Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MRD”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT05929222
What this trial is testing

Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Who this might be right for
Follicular Lymphoma
Fondazione Italiana Linfomi - ETS 190
Early research (Phase 1)Ended earlyNCT05001451
What this trial is testing

Study of GDX012 in Patients With MRD Positive AML

Who this might be right for
Acute Myeloid Leukemia
GammaDelta Therapeutics Limited 3
Testing effectiveness (Phase 2)Study completedNCT04010968
What this trial is testing

Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia

Who this might be right for
Intermediate Risk Chronic Lymphocytic LeukemiaFit PatientsRisk-Adapted and MRD-Driven Strategy
French Innovative Leukemia Organisation 120
Not applicableUnknownNCT05458115
What this trial is testing

Clinical Study of MRD Recurrence Monitoring After Surgical Resection of Hepatocellular Carcinoma

Who this might be right for
HCC
Anhui Provincial Hospital 200
Not applicableUnknownNCT05426850
What this trial is testing

CtDNA-based MRD Assessment in Local Advanced Esophageal Carcinoma

Who this might be right for
Esophageal Squamous Cell Carcinoma
Fudan University 100
Testing effectiveness (Phase 2)Ended earlyNCT02349178
What this trial is testing

Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT

Who this might be right for
Leukemia, Acute LymphoblasticAcute Myeloid Leukemia
Medical College of Wisconsin 6
Not applicableActive Not RecruitingNCT00959140
What this trial is testing

Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Related Donors

Who this might be right for
Hematopoietic Stem Cell Transplantation
University of Alabama at Birmingham 20
Testing effectiveness (Phase 2)Looking for participantsNCT05872724
What this trial is testing

Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)

Who this might be right for
Cervical Cancer
Suzhou Municipal Hospital 32
Not applicableStudy completedNCT01326143
What this trial is testing

Narval CC Mandibular Repositioning Device in the Second-line Treatment of Severe Obstructive Sleep Apnea Hypopnea (OSAH)

Who this might be right for
Obstructive Sleep Apnea Syndrome
ResMed 360
Not applicableUnknownNCT06267144
What this trial is testing

Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer
The First Hospital of Jilin University 20
Not applicableStudy completedNCT06000306
What this trial is testing

MRD Monitoring by Digital Droplet PCR in the Early Period After Allo-HSCT to Predict Patients at High Risk of Relapse

Who this might be right for
Measurable Residual Disease
Zhejiang University 192
Large-scale testing (Phase 3)Study completedNCT01084720
What this trial is testing

Efficacy, Local Tolerance and Patient Acceptability of a Moisturizing Emollient in Patients With Uremic Xerosis

Who this might be right for
Uremic Xerosis
Orfagen 100
Testing effectiveness (Phase 2)Looking for participantsNCT03737955
What this trial is testing

Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
University of Washington 36
Testing effectiveness (Phase 2)WithdrawnNCT05604755
What this trial is testing

Prophylactic HQP1351 Therapy Post-transplants on Leukemia After Allo-HSCT

Who this might be right for
Prophylactic HQP1351 TherapyThird Generation TKI
xuna
Testing effectiveness (Phase 2)UnknownNCT05821738
What this trial is testing

Avapritinib in CBF-AML With KIT Mutations

Who this might be right for
Core Binding Factor Acute Myeloid LeukemiaKIT Mutation-Related Tumors
The First Affiliated Hospital of Soochow University 50
Not applicableLooking for participantsNCT06918262
What this trial is testing

Observational Clinical Study on Role of MRD in Predicting Local Therapy in Oligometastatic Breast Cancer

Who this might be right for
Breast CancerMRD
The First Hospital of Jilin University 40
Testing effectiveness (Phase 2)Ended earlyNCT04044560
What this trial is testing

Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant

Who this might be right for
B-cell Adult Acute Lymphoblastic LeukemiaStem Cell LeukemiaMinimal Residual Disease
University of British Columbia 8
Not applicableLooking for participantsNCT06287723
What this trial is testing

French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)

Who this might be right for
Colorectal CancerLiver MetastasesStage IV Colorectal Cancer+3 more
University Hospital, Montpellier 30
Testing effectiveness (Phase 2)UnknownNCT03992170
What this trial is testing

Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive

Who this might be right for
Myeloma Multiple
Azienda Ospedaliera Universitaria Senese 50
Early research (Phase 1)Ended earlyNCT01743807
What this trial is testing

Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia

Who this might be right for
Relapsed Acute Lymphoblastic LeukemiaRelapsed Acute Myelogenous Leukemia
Therapeutic Advances in Childhood Leukemia Consortium 4
Next Page